Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Gueny ME, Sahm DF.

J Antimicrob Chemother. 2019 Aug 1;74(8):2284-2288. doi: 10.1093/jac/dkz191.

PMID:
31086960
2.

The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.

Huang DB, Charrier C, Le Bras C, Hawser S, Noviello S.

J Med Microbiol. 2019 Jun;68(6):898-902. doi: 10.1099/jmm.0.000989. Epub 2019 May 3.

PMID:
31050628
3.

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015.

Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00514-19. doi: 10.1128/AAC.00514-19. Print 2019 Jul.

4.

In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections.

Noviello S, Magnet S, Hawser S, Huang DB.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02239-18. doi: 10.1128/AAC.02239-18. Print 2019 Apr.

PMID:
30642922
5.

In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016.

Noviello S, Hawser S, Sader H, Huang DB.

J Glob Antimicrob Resist. 2019 Mar;16:236-238. doi: 10.1016/j.jgar.2018.10.018. Epub 2018 Oct 26.

PMID:
30612987
6.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.

J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879. doi: 10.1093/jac/dky107.

PMID:
29659861
7.

In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.

Aliouat EM, Dei-Cas E, Gantois N, Pottier M, Pinçon C, Hawser S, Lier A, Huang DB.

Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):409-415. doi: 10.1007/s10096-018-3184-z. Epub 2018 Jan 12.

PMID:
29330709
8.

Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres.

Huang DB, Morrissey I, Murphy T, Hawser S, Wilcox MH.

Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):673-678. doi: 10.1007/s10096-017-3159-5. Epub 2017 Dec 8.

9.

Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections.

Hawser S, Morrissey I, Lemos B, Keedy K, Fernandes P.

Int J Antimicrob Agents. 2017 Jul;50(1):17-22. doi: 10.1016/j.ijantimicag.2017.01.035. Epub 2017 May 5.

PMID:
28483717
10.

In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study.

Huang DB, Hawser S, Gemmell CG, Sahm DF.

Can J Infect Dis Med Microbiol. 2017;2017:3948626. doi: 10.1155/2017/3948626. Epub 2017 Dec 17.

11.

Activity of RX-P873, a novel pyrrolocytosine, against Gram-negative bacteria.

Morrissey I, Magnet S, Genet E, Jeandey P, Marra A, Hawser S, Duffy E.

Int J Antimicrob Agents. 2015 Sep;46(3):352-4. doi: 10.1016/j.ijantimicag.2015.06.001. Epub 2015 Jun 19. No abstract available.

PMID:
26159867
12.

Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012.

Biedenbach D, Bouchillon S, Hackel M, Hoban D, Kazmierczak K, Hawser S, Badal R.

Antimicrob Agents Chemother. 2015 Feb;59(2):826-30. doi: 10.1128/AAC.03938-14. Epub 2014 Nov 17.

13.

In vitro susceptibility and distribution of beta-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011.

Hoban DJ, Badal R, Bouchillon S, Hackel M, Kazmierczak K, Lascols C, Hawser S.

Diagn Microbiol Infect Dis. 2014 Jul;79(3):367-72. doi: 10.1016/j.diagmicrobio.2014.03.026. Epub 2014 Apr 12.

PMID:
24813688
14.

Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011.

Hawser S, Hoban DJ, Badal RE, Bouchillon SK, Biedenbach D, Hackel M, Morrissey I.

J Chemother. 2015 Feb;27(2):67-73. doi: 10.1179/1973947814Y.0000000164. Epub 2014 Feb 18.

PMID:
24548089
15.

Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.

Morrissey I, Bouchillon SK, Hackel M, Biedenbach DJ, Hawser S, Hoban D, Badal RE.

J Med Microbiol. 2014 Apr;63(Pt 4):556-61. doi: 10.1099/jmm.0.068981-0. Epub 2014 Jan 29.

PMID:
24478449
16.

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.

Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D.

Pharmaceuticals (Basel). 2013 Nov 1;6(11):1335-46. doi: 10.3390/ph6111335.

17.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA.

J Infect. 2014 Jan;68(1):71-6. doi: 10.1016/j.jinf.2013.09.001. Epub 2013 Sep 7.

PMID:
24016768
19.
20.

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010.

Babinchak T, Badal R, Hoban D, Hackel M, Hawser S, Lob S, Bouchillon S.

Diagn Microbiol Infect Dis. 2013 Jul;76(3):379-81. doi: 10.1016/j.diagmicrobio.2013.02.031. Epub 2013 Mar 27.

PMID:
23541118
21.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

Lob SH, Badal RE, Bouchillon SK, Hawser SP, Hackel MA, Hoban DJ.

Surg Infect (Larchmt). 2013 Apr;14(2):203-8. doi: 10.1089/sur.2012.034. Epub 2013 Mar 29.

PMID:
23540793
22.

Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Biedenbach DJ, Cantón R, Paterson DL.

Int J Antimicrob Agents. 2013 Mar;41(3):224-8. doi: 10.1016/j.ijantimicag.2012.10.014. Epub 2013 Jan 8.

PMID:
23305657
23.

Surveillance programmes and antibiotic resistance: worldwide and regional monitoring of antibiotic resistance trends.

Hawser S.

Handb Exp Pharmacol. 2012;(211):31-43. doi: 10.1007/978-3-642-28951-4_3. Review.

PMID:
23090594
24.

Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010.

Bouchillon S, Hoban DJ, Badal R, Hawser S.

Open Microbiol J. 2012;6:74-8. Epub 2012 Sep 7.

25.

Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010.

Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, Hawser S.

Diagn Microbiol Infect Dis. 2012 Sep;74(1):62-7. doi: 10.1016/j.diagmicrobio.2012.05.024. Epub 2012 Jul 2.

PMID:
22763019
26.

Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hackel MA, Lascols CA, Villegas MV, Rossi F.

J Chemother. 2012 Feb;24(1):6-11. doi: 10.1179/1120009X12Z.0000000003.

PMID:
22546718
27.

Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.

Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC.

Int J Antimicrob Agents. 2012 Jun;39(6):490-5. doi: 10.1016/j.ijantimicag.2012.02.018. Epub 2012 Apr 23.

PMID:
22534507
28.

Susceptibility of global intra-abdominal Enterobacteriaceae isolates to tigecycline (TEST 2007-2010).

Hawser SP, Lob S, Hoban D, Bouchillon S, Badal R.

J Infect. 2012 Jun;64(6):620-2. doi: 10.1016/j.jinf.2012.02.002. Epub 2012 Feb 8. No abstract available.

PMID:
22326560
29.

Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world.

Lascols C, Hackel M, Hujer AM, Marshall SH, Bouchillon SK, Hoban DJ, Hawser SP, Badal RE, Bonomo RA.

J Clin Microbiol. 2012 May;50(5):1632-9. doi: 10.1128/JCM.06115-11. Epub 2012 Feb 8.

30.
31.

Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010.

Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R.

Diagn Microbiol Infect Dis. 2011 Aug;70(4):507-11. doi: 10.1016/j.diagmicrobio.2011.03.021.

PMID:
21767706
32.

Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates.

Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Woodford N, Livermore DM.

Antimicrob Agents Chemother. 2011 Aug;55(8):3917-21. doi: 10.1128/AAC.00070-11. Epub 2011 Jun 13.

33.

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).

Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Cantón R.

Clin Microbiol Infect. 2012 Mar;18(3):253-9. doi: 10.1111/j.1469-0691.2011.03550.x. Epub 2011 Jun 2.

34.

Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).

Hawser SP.

Int J Antimicrob Agents. 2011 Aug;38(2):186-7. doi: 10.1016/j.ijantimicag.2011.04.008. Epub 2011 May 31. No abstract available.

PMID:
21632217
35.

Superior activity of colistin against Pseudomonas aeruginosa clinical isolates, including multidrug-resistant isolates, from multiple infection sources from 2007 to 2009.

Hawser SP.

Int J Antimicrob Agents. 2011 Jun;37(6):587. doi: 10.1016/j.ijantimicag.2011.02.011. Epub 2011 Apr 13. No abstract available.

PMID:
21493045
36.

Activity of ertapenem and comparators against recent clinical isolates from intra-abdominal abscesses (SMART 2009).

Hawser SP.

J Infect. 2011 Jun;62(6):496-7. doi: 10.1016/j.jinf.2011.03.008. Epub 2011 Mar 31. No abstract available.

PMID:
21458487
37.

Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.

Chen YH, Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, Paterson DL.

J Infect. 2011 Apr;62(4):280-91. doi: 10.1016/j.jinf.2011.02.009. Epub 2011 Mar 5.

PMID:
21382411
38.

Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.

Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T.

Int J Antimicrob Agents. 2011 Mar;37(3):219-24. doi: 10.1016/j.ijantimicag.2010.10.029. Epub 2011 Jan 15.

PMID:
21239146
39.

Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008.

Hawser S, Hoban D, Bouchillon S, Badal R, Carmeli Y, Hawkey P.

Eur J Clin Microbiol Infect Dis. 2011 Feb;30(2):173-9. doi: 10.1007/s10096-010-1066-0. Epub 2010 Oct 16.

PMID:
20953653
40.

Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, Paterson DL; 2008 Asia–Pacific SMART Group.

Int J Antimicrob Agents. 2010 Nov;36(5):408-14. doi: 10.1016/j.ijantimicag.2010.07.002. Epub 2010 Aug 21.

PMID:
20728316
42.

Susceptibility of Klebsiella pneumoniae clinical isolates from 2007 to 2009 to colistin and comparator antibiotics.

Hawser SP.

Int J Antimicrob Agents. 2010 Oct;36(4):383-4. doi: 10.1016/j.ijantimicag.2010.06.004. Epub 2010 Jul 31. No abstract available.

PMID:
20674285
43.

Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR.

Int J Antimicrob Agents. 2010 Sep;36(3):293-4. doi: 10.1016/j.ijantimicag.2010.05.012. Epub 2010 Jul 3. No abstract available.

PMID:
20598511
44.

In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii.

Hawser SP, Hackel M, Person MB, Higgins PG, Seifert H, Dowzicky M.

Int J Antimicrob Agents. 2010 Sep;36(3):289-90. doi: 10.1016/j.ijantimicag.2010.04.009. Epub 2010 Jun 16. No abstract available.

PMID:
20558046
45.

Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ; SMART India Working Group.

J Med Microbiol. 2010 Sep;59(Pt 9):1050-4. doi: 10.1099/jmm.0.020784-0. Epub 2010 Jun 10.

PMID:
20538892
46.

Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe.

Hawser SP.

Eur J Clin Microbiol Infect Dis. 2010 Aug;29(8):1011-3. doi: 10.1007/s10096-010-0962-7. Epub 2010 May 23.

PMID:
20496091
47.

Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J.

Antimicrob Agents Chemother. 2010 Jul;54(7):3031-4. doi: 10.1128/AAC.01808-09. Epub 2010 May 10.

49.

Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009.

Hawser SP.

J Infect. 2010 May;60(5):401-2. doi: 10.1016/j.jinf.2010.03.001. Epub 2010 Mar 6. No abstract available.

PMID:
20211200
50.

Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).

Hawser SP.

J Infect. 2010 Apr;60(4):306-8. doi: 10.1016/j.jinf.2010.02.003. Epub 2010 Feb 8. No abstract available.

PMID:
20144899

Supplemental Content

Loading ...
Support Center